A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)
Status:
Terminated
Trial end date:
2008-08-26
Target enrollment:
Participant gender:
Summary
A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary
hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a
decrease in lower extremity atherosclerotic plaque macrophage content when compared to
placebo (an approximate decrease of up to 30% is expected).